Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide
- Development stage
- Phase 2
- Lead developer
- BioVersys
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy for tuberculosis that includes alpibectir, a novel small molecule that significantly potentiates the activity of ethionamide by acting on transcriptional regulators of Mycobacterium tuberculosis (Mtb), along with standard first-line TB drugs (rifampicin, ethambutol, and pyrazinamide). Alpibectir stimulates novel bioactivation pathways for ethionamide, increasing its efficacy while simultaneously overcoming ethionamide resistance. The combination is being developed for pulmonary and meningeal tuberculosis.
02
Targets
AftA (Arabinosyltransferase AftA)rpoB (DNA-directed RNA polymerase subunit beta)EthR;EthR2 (EthR/EthR2)InhAMultiple pyrazinamide-associated bacterial targets/processesVirS (VirS sensor histidine kinase)TF (Transferrin)
Beyond the preview
Go deeper on alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpibectir + ethionamide + rifampicin + ethambutol + pyrazinamide.